ClinicalTrials.gg
RecruitingNCT07609095PULSARUpdated Aug 18, 2026

Peripheral pULSe Assessment and Arterial pRessure (PULSAR)

An observational study in Circulatory Shock, Hemodynamic Instability and Hypotension, sponsored by Region Stockholm. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Region Stockholm · Observational

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,000
Ages
18 Years and older
Sex
All
01

Study summary

This prospective multicenter observational study aims to investigate the relationship between palpable peripheral pulses and simultaneously measured arterial blood pressure in adult patients with circulatory shock or impending circulatory failure. Peripheral pulse palpation is routinely used in emergency medicine, trauma care, critical care, and cardiopulmonary resuscitation as a rapid clinical assessment of circulation. However, the association between palpable pulses and actual arterial blood pressure remains poorly validated.

Patients treated in emergency departments, intensive care units, operating rooms, and other acute care settings will undergo routine pulse palpation at predefined anatomical locations including carotid, femoral, and radial arteries. Simultaneously measured non-invasive and/or invasive arterial blood pressure values will be recorded from routine clinical monitoring systems. Additional clinical variables relevant to circulatory status will also be collected.

The study seeks to define blood pressure thresholds associated with pulse palpability and evaluate the agreement between invasive and non-invasive blood pressure measurements in patients with circulatory shock.

Read the detailed description

The presence or absence of palpable peripheral pulses is widely used as a rapid bedside indicator of circulatory status during trauma care, emergency medicine, intensive care, and cardiopulmonary resuscitation. Advanced Trauma Life Support (ATLS) teaching traditionally assumes that palpable pulses at different anatomical sites correspond to specific systolic blood pressure thresholds. However, these assumptions are based on limited evidence from small observational studies.

This international multicenter prospective observational cohort study aims to investigate the relationship between palpable carotid, femoral, and radial pulses and simultaneously measured arterial blood pressure in adult patients with circulatory shock or impending circulatory failure.

Patients receiving routine hemodynamic monitoring with non-invasive blood pressure (NIBP) and/or invasive arterial blood pressure (IBP) monitoring will be included. Pulse palpation will be performed during routine clinical care without altering treatment or management.

The primary objective is to determine the association between pulse palpability and measured systolic blood pressure. Secondary objectives include identifying blood pressure thresholds associated with pulse palpability, evaluating agreement between invasive and non-invasive blood pressure measurements, and assessing whether patient factors such as vascular disease or vasoactive medication use influence pulse palpability.

02

Conditions studied

  • Circulatory Shock
  • Hemodynamic Instability
  • Hypotension
  • Shock
  • Critical Illness

Keywords

  • Circulatory Shock
  • Hemodynamic Monitoring
  • Pulse Palpation
  • Peripheral Pulse
  • Arterial Blood Pressure
  • Hypotension
  • Critical Care
  • Trauma
  • Resuscitation
  • Hemodynamic Instability
03

In context

Shock

487 studies on the registry are indexed under Shock; 107 are open to participants now.

This study's planned enrollment of 5,000 is above the median of 100 across 247 observational studies indexed under Shock.

Browse Shock studies →

Lead sponsor

Region Stockholm is the lead sponsor of 121 studies on the registry; 69 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with circulatory shock or impending circulatory failure treated in emergency departments, intensive care units, operating rooms, trauma centers, and other acute care settings.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical signs of circulatory shock or impending circulatory failure
  • Availability of non-invasive and/or invasive arterial blood pressure monitoring
  • Pulse palpation possible without interfering with emergency care

Exclusion criteria

Exclusion Criteria:

  • Peripheral vascular conditions preventing reliable pulse palpation
  • Major extremity amputation affecting assessment sites
  • Clinical situations where study procedures interfere with life-saving treatment
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients With Circulatory Shock

    Adult patients with clinical signs of circulatory shock or impending circulatory failure undergoing routine hemodynamic monitoring with non-invasive and/or invasive arterial blood pressure measurement during standard clinical care.

    Procedure: Peripheral Pulse Palpation

Interventions

  • ProcedurePeripheral Pulse Palpation

    Manual palpation of carotid, femoral, and radial pulses performed during routine clinical care in patients with circulatory instability. Simultaneous arterial blood pressure measurements are recorded from standard monitoring systems. No study-specific treatment or intervention is administered.

06

What researchers measure

Primary outcomes

  1. Association between palpable pulses and systolic arterial blood pressure

    Relationship between palpable carotid, femoral, and radial pulses and simultaneously measured systolic arterial blood pressure.

    Time frame: During episodes of circulatory instability, up to 24 hours after inclusion

Secondary outcomes

  1. Mean arterial pressure associated with pulse palpability

    Relationship between pulse palpability and mean arterial pressure (MAP).

    Time frame: During episodes of circulatory instability, up to 24 hours after inclusion

  2. Agreement between non-invasive and invasive blood pressure measurements

    Agreement between oscillometric non-invasive blood pressure and invasive arterial blood pressure measurements.

    Time frame: During episodes of circulatory instability, up to 24 hours after inclusion

  3. Effect of vascular disease and vasoactive medication on pulse palpability

    Influence of peripheral vascular disease, atherosclerosis, age, and vasoactive medications on pulse palpability.

    Time frame: During hospital admission, up to 30 days

07

Study locations

1 of 1 sites recruiting
  • Region Stockholm, all hospitals
    Stockholm, Stockholm County 11883, Sweden
    Recruiting
08

References and documents

Publications

  • Gunther M, Dahlberg M, Rostami A, Azadali A, Arborelius UP, Linder F, Rostami E. Incidence, Demographics, and Outcomes of Penetrating Trauma in Sweden During the Past Decade. Front Neurol. 2021 Nov 15;12:730405. doi: 10.3389/fneur.2021.730405. eCollection 2021. PubMed 34867718 ↗
  • Kim SH, Lilot M, Sidhu KS, Rinehart J, Yu Z, Canales C, Cannesson M. Accuracy and precision of continuous noninvasive arterial pressure monitoring compared with invasive arterial pressure: a systematic review and meta-analysis. Anesthesiology. 2014 May;120(5):1080-97. doi: 10.1097/ALN.0000000000000226. PubMed 24637618 ↗

Individual participant data

Plan to share: Undecided — Data sharing plans are currently undecided due to ongoing considerations regarding ethical approvals, multicenter collaboration agreements, and data protection regulations.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2031, 60 months after the start.

Of 120 non-industry observational studies under Shock, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 52. This study's planned 60 months is above that.

Counting every sponsor, half of 127 studies reached it within 26 months; a quarter within 12 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2026
First posted
May 27, 2026
StartActual
Jun 1, 2026
Primary completionEst.
Jun 1, 2031
CompletionEst.
Dec 31, 2031
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07609095
Lead sponsor
Region Stockholm
Responsible party
Mattias Gunther (MD PhD Associate Professor, Region Stockholm) — Principal investigator
First posted
May 27, 2026
Start date
Jun 1, 2026
Primary completion
Jun 1, 2031 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Aug 18, 2026

Study contacts

Mattias Günther, MD PhD
Contact
mattias.gunther@ki.se
46812361000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion